ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Panobinostat (LBH589)
Sponsor: Tulane University Health Sciences Center
Collaborators: Novartis|Board of Regents, State of Louisiana